Onconetix Inc. (ONCO) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ONCO scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 5 of 20 (ROIC -35%; FCF yield 0%); Whale 13F Flow at 7 of 20 (institutional accumulation and options positioning); Insider Conviction at 3 of 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 7 of 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 8 of 20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are the cash engine and insider conviction, which together suggest the business is not currently converting activity into free cash flow and that insiders are not signaling confidence. The forensic balance sheet pillar is also weak, with a Piotroski F-Score of 3 out of 9 pointing to limited financial strength. The most constructive pillars, whale flow and macro fit, sit at 7 of 20 each and do not offset the fundamental weakness. Any upside case would rest on a change in the cash engine that the source data does not show. The rating is presented as a structured framework and not as personalized advice.

Per the market data, operating margin and net margin are both -60%, gross margin is 77.6%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3 out of 9, and Debt/Equity is 0.5. Cash and debt balances are N/A in the SEC financials, so balance sheet posture beyond these ratios cannot be confirmed from the source data.

Per the recent news feed, the dominant item is a 1-for-10 reverse stock split announced for effectiveness on November 6, 2026, reported across multiple outlets including Moomoo, Investing.com, TradingView, and GlobeNewswire. A reverse split is a mechanical share-count change and does not by itself alter the underlying business. A separate item reports that RBC raised its price target on Onconetix to $459 from $450 and kept an Outperform rating, flagged as a catalyst. The price target figure is inconsistent with a $0.59 share price and a $3.5M market cap and should be treated as unverified. The Butterfly Supply-Chain Graph reports no supply chain and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data.

• What are the company's products and revenue sources, given the profile and business description are not provided?
• What are the cash and debt balances, since the SEC financials report these as N/A?
• Why does the market data show EPS and P/E as unavailable while net income is reported as negative?
• Does the RBC price target reference correspond to this listing, given its scale is inconsistent with the share price?
• What is the impact of the 1-for-10 reverse split on share count and the 52-week range?